174 related articles for article (PubMed ID: 28848667)
1.
Sharma A; Tilak T; Bakhshi S; Raina V; Kumar L; Chaudhary S; Sahoo R; Gupta R; Thulkar S
ESMO Open; 2016; 1(6):e000138. PubMed ID: 28848667
[TBL] [Abstract][Full Text] [Related]
2. Lactobacillus brevis CD2 lozenges reduce radiation- and chemotherapy-induced mucositis in patients with head and neck cancer: a randomized double-blind placebo-controlled study.
Sharma A; Rath GK; Chaudhary SP; Thakar A; Mohanti BK; Bahadur S
Eur J Cancer; 2012 Apr; 48(6):875-81. PubMed ID: 21741230
[TBL] [Abstract][Full Text] [Related]
3.
DE Sanctis V; Belgioia L; Cante D; LA Porta MR; Caspiani O; Guarnaccia R; Argenone A; Muto P; Musio D; DE Felice F; Maurizi F; Bunkhelia F; Ruo Redda MG; Reali A; Valeriani M; Osti MF; Alterio D; Bacigalupo A; Russi EG
Anticancer Res; 2019 Apr; 39(4):1935-1942. PubMed ID: 30952736
[TBL] [Abstract][Full Text] [Related]
4. Polaprezinc for prevention of oral mucositis in patients receiving chemotherapy followed by hematopoietic stem cell transplantation: A multi-institutional randomized controlled trial.
Kitagawa J; Kobayashi R; Nagata Y; Kasahara S; Ono T; Sawada M; Ohata K; Kato-Hayashi H; Hayashi H; Shimizu M; Itoh Y; Tsurumi H; Suzuki A
Int J Cancer; 2021 Mar; 148(6):1462-1469. PubMed ID: 32984946
[TBL] [Abstract][Full Text] [Related]
5. Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy.
Riley P; Glenny AM; Worthington HV; Littlewood A; Clarkson JE; McCabe MG
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011552. PubMed ID: 26695736
[TBL] [Abstract][Full Text] [Related]
6. Effect of a daily dose of Lactobacillus brevis CD2 lozenges in high caries risk schoolchildren.
Campus G; Cocco F; Carta G; Cagetti MG; Simark-Mattson C; Strohmenger L; Lingström P
Clin Oral Investig; 2014; 18(2):555-61. PubMed ID: 23644602
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of
Shah MP; Gujjari SK; Chandrasekhar VS
J Indian Soc Periodontol; 2017; 21(4):341-343. PubMed ID: 29456312
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study.
Yokota T; Ogawa T; Takahashi S; Okami K; Fujii T; Tanaka K; Iwae S; Ota I; Ueda T; Monden N; Matsuura K; Kojima H; Ueda S; Sasaki K; Fujimoto Y; Hasegawa Y; Beppu T; Nishimori H; Hirano S; Naka Y; Matsushima Y; Fujii M; Tahara M
BMC Cancer; 2017 May; 17(1):314. PubMed ID: 28476132
[TBL] [Abstract][Full Text] [Related]
9. Anakinra: efficacy in the management of fever during neutropenia and mucositis in autologous stem cell transplantation (AFFECT-2)-study protocol for a multicenter randomized double-blind placebo-controlled trial.
de Mooij CEM; van Groningen LFJ; de Haan AFJ; Biemond BJ; Bakker M; van der Velden WJFM; Blijlevens NMA
Trials; 2020 Nov; 21(1):948. PubMed ID: 33225965
[TBL] [Abstract][Full Text] [Related]
10. Multi-Sensor Approach for the Monitoring of Halitosis Treatment via Lactobacillus brevis (CD2)-Containing Lozenges--A Randomized, Double-Blind Placebo-Controlled Clinical Trial.
Marchetti E; Tecco S; Santonico M; Vernile C; Ciciarelli D; Tarantino E; Marzo G; Pennazza G
Sensors (Basel); 2015 Aug; 15(8):19583-96. PubMed ID: 26266414
[TBL] [Abstract][Full Text] [Related]
11. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Sun XS; Tao Y; Le Tourneau C; Pointreau Y; Sire C; Kaminsky MC; Coutte A; Alfonsi M; Boisselier P; Martin L; Miroir J; Ramee JF; Delord JP; Clatot F; Rolland F; Villa J; Magne N; Elicin O; Gherga E; Nguyen F; Lafond C; Bera G; Calugaru V; Geoffrois L; Chauffert B; Zubel A; Zanna C; Brienza S; Crompton P; Rouits E; Gollmer K; Szyldergemajn S; Bourhis J
Lancet Oncol; 2020 Sep; 21(9):1173-1187. PubMed ID: 32758455
[TBL] [Abstract][Full Text] [Related]
12. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
13. The incidence of severe oral mucositis in patients undergoing different conditioning regimens in haematopoietic stem cell transplantation.
Nakagaki M; Kennedy GA; Gavin NC; Clavarino A; Whitfield K
Support Care Cancer; 2022 Nov; 30(11):9141-9149. PubMed ID: 36008731
[TBL] [Abstract][Full Text] [Related]
14. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs.
Mantovani G; Massa E; Astara G; Murgia V; Gramignano G; Lusso MR; Camboni P; Ferreli L; Mocci M; Perboni S; Mura L; Madeddu C; Macciò A
Oncol Rep; 2003; 10(1):197-206. PubMed ID: 12469169
[TBL] [Abstract][Full Text] [Related]
15. Viable Bifidobacterium tablets for the prevention of chemotherapy-/radiation-induced mucositis in patients undergoing haematopoietic stem cell transplantation.
Guo J; Zhang H; Lu X; Xia L
Support Care Cancer; 2023 Apr; 31(5):282. PubMed ID: 37074462
[TBL] [Abstract][Full Text] [Related]
16. Lactobacillus brevis CD2 attenuates traumatic oral lesions induced by fixed orthodontic appliance: A randomized phase 2 trial.
Silva NLNV; Della Bona A; Cardoso M; Callegari-Jacques SM; Fornari F
Orthod Craniofac Res; 2021 Aug; 24(3):379-385. PubMed ID: 33259688
[TBL] [Abstract][Full Text] [Related]
17. Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study.
Gouvêa de Lima A; Villar RC; de Castro G; Antequera R; Gil E; Rosalmeida MC; Federico MH; Snitcovsky IM
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):270-5. PubMed ID: 21163585
[TBL] [Abstract][Full Text] [Related]
18. Prevention and Treatment of Chemotherapy and Radiotherapy Induced Oral Mucositis.
Daugėlaitė G; Užkuraitytė K; Jagelavičienė E; Filipauskas A
Medicina (Kaunas); 2019 Jan; 55(2):. PubMed ID: 30678228
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic Effect of Polaprezinc, a Zinc-L-carnosine, Against Chemotherapy-induced Oral Mucositis in Pediatric Patients Undergoing Autologous Stem Cell Transplantation.
Funato M; Ozeki M; Suzuki A; Ishihara M; Kobayashi R; Nozawa A; Yasue S; Endo-Ohnishi S; Fukao T; Itoh Y
Anticancer Res; 2018 Aug; 38(8):4691-4697. PubMed ID: 30061237
[TBL] [Abstract][Full Text] [Related]
20. The influence of Lactobacillus brevis on ornithine decarboxylase activity and polyamine profiles in Helicobacter pylori-infected gastric mucosa.
Linsalata M; Russo F; Berloco P; Caruso ML; Matteo GD; Cifone MG; Simone CD; Ierardi E; Di Leo A
Helicobacter; 2004 Apr; 9(2):165-72. PubMed ID: 15068419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
